Cargando…
Current Management Options in Metastatic Renal Cell Cancer
Renal cancer accounts for 2.4% of all cancers. Localised disease accounts for the majority of renal cancers (70-75%), however 20-25% of these ultimately develop distant metastasis. The median overall survival of un treated metastatic disease is 5 months with 1-year survival of only 29%. The manageme...
Autor principal: | Gangadaran, Sittu Govindasamy Dinakaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481727/ https://www.ncbi.nlm.nih.gov/pubmed/28680539 http://dx.doi.org/10.4081/oncol.2017.339 |
Ejemplares similares
-
Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022) -
Dengue and Psychiatry: Manifestations, Mechanisms, and Management
Options
por: Dinakaran, Damodharan, et al.
Publicado: (2021) -
New treatment options for metastatic renal cell carcinoma
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2017) -
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019) -
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
por: Dietvorst, Maria H. P., et al.
Publicado: (2013)